Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (Nasdaq: DTIL), a Delaware corporation, filed this Current Report on Form 8-K on August 14, 2019. The filing serves to announce the company's financial results for the quarter ended June 30, 2019. The registrant is classified as an emerging growth company.
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the full text of the press release containing these results is furnished as Exhibit 99.1 and incorporated by reference, but the data itself is not present in the main body of this document.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document functions solely as a notification that results have been issued, deferring to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in this Current Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that Section. No specific guidance, management commentary, risks, or contingencies are described in the text provided.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2019, by reviewing Exhibit 99.1 (Press Release) attached to the filing.
- Confirm the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Note that the financial data in this 8-K is not deemed "filed" under Section 18 of the Exchange Act, limiting liability protections for the disclosed information.